Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
MOTS-c: Evidence Summary
Evidence summary for MOTS-c across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to MOTS-c overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Metabolic regulation | Tier C | 1 | Mitochondria-derived peptide improves glucose homeostasis in early human studies |
| Insulin sensitivity | Tier C | 1 | Improved glucose disposal in obese subjects in pilot study |
| Exercise mimetic | Tier D | 0 | Activates AMPK and enhances fatty acid oxidation in preclinical models |
References (6)
- Mitochondrial dysfunction characterises the multigenerational effects of maternal obesity on MASLD. . JHEP reports (2025) PMID: 40496439
- MOTS-c-modified functional self-assembly peptide hydrogels enhance the activity of nucleus pulposus-derived mesenchymal stem cells of intervertebral disc degeneration. . Materials today. Bio (2025) PMID: 40510834
- The Role of Mitokines in Diabetic Nephropathy. . Current medicinal chemistry (2025) PMID: 37921178
- MOTS-c is an effective target for treating cancer-induced bone pain through the induction of AMPK-mediated mitochondrial biogenesis. . Acta biochimica et biophysica Sinica (2024) PMID: 38716540
- Neuroprotective Mechanism of MOTS-c in TBI Mice: Insights from Integrated Transcriptomic and Metabolomic Analyses. . Drug design, development and therapy (2024) PMID: 39050800
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. — Lee C, et al. . Cell Metabolism (2015) PMID: 25738459